Can NAD Supplements Cause Heart Palpitations?

No clinical trial of NAD-boosting supplements has reported heart palpitations as a side effect, and the adverse events that do show up in human studies tend to be mild and unrelated to heart rhythm. That said, the question is more interesting than a flat “no” suggests. NAD sits at the center of cardiac energy metabolism, and laboratory research on heart cells shows that shifting the balance of NAD and its reduced form, NADH, can directly alter the electrical behavior of the heart. The gap between what happens in a petri dish and what happens when you swallow a capsule is wide, but it is worth understanding why some supplement users report a racing or fluttering heartbeat even if formal trials have not confirmed the link.

What NAD Supplements Actually Are

When people talk about “NAD supplements,” they almost always mean precursor molecules that the body converts into NAD+ after ingestion. The three you will encounter most are nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and plain nicotinamide (also called niacinamide). None of these deliver NAD+ directly to your cells. Tracer studies in mice and early human pharmacokinetic work show that orally administered NR and NMN undergo substantial breakdown in the gut and liver before they ever reach the bloodstream, so only a small fraction arrives intact at target tissues.¹ Much of the NAD+ boost appears to happen indirectly: the gut microbiome converts breakdown products into nicotinic acid, which the body then reassembles into NAD+ through a separate biochemical route.² This matters for the palpitation question because it means the cellular NAD+ increase from a supplement is gradual and distributed, not a sudden spike in the heart.

What Human Trials Say About Side Effects

The most reassuring evidence comes from randomized, placebo-controlled trials that tracked adverse events carefully. In a study of healthy overweight adults who took NR at doses of 100, 300, or 1,000 mg daily for eight weeks, the rate and severity of side effects were similar across all dose groups and the placebo group. No flushing was reported, and the events flagged as possibly related to the supplement were things like mild nausea, muscle soreness, and in one case, elevated blood pressure. All resolved by the end of the study.³ A separate trial of NMN supplementation in middle-aged and older adults found the same pattern: roughly 3% of participants in both the active and placebo groups reported mild adverse events, with no clinically meaningful changes in safety labs.⁴

A high-dose trial in people with Parkinson’s disease, where participants took 3,000 mg of NR daily, also found no significant difference in adverse event frequency between the supplement and placebo groups. All events were graded as mild.⁵ Across these trials, heart palpitations, arrhythmia, and tachycardia simply do not appear in the adverse-event tables. That does not prove palpitations are impossible, but it does mean they are not a common or dose-limiting side effect at the amounts studied.

Why the Biology Makes the Question Reasonable

Even though clinical trials are reassuring, the concern is not baseless. NAD+ and NADH are deeply embedded in the electrical machinery of the heart, and laboratory experiments have uncovered several ways that shifting their balance can change heart rhythm at the cellular level.

In isolated rat heart cells, increasing the NADH-to-NAD+ ratio depressed calcium release from the internal stores that drive each heartbeat. NADH directly inhibited the channel responsible for releasing calcium and also reduced the pump that reloads those stores, lowering the cell’s overall calcium content by about half.⁶ Calcium handling is one of the main determinants of whether a heartbeat is normal or irregular, so any substance that shifts this balance has theoretical arrhythmia relevance.

The story extends to sodium channels. When NADH levels rise inside heart cells, it triggers a chain of events involving mitochondrial stress signals that reduce the sodium current responsible for rapid electrical conduction. In animal models of cardiomyopathy, this reduced sodium current was associated with conduction problems and arrhythmia risk. Restoring NAD+ reversed the effect and improved conduction velocity, even in tissue from human hearts with disease.⁷ The same research group confirmed that altering the oxidized-to-reduced NAD balance can activate mitochondrial stress signals that reduce sodium current, creating a mechanistic link between metabolism and arrhythmia.⁸

There is even evidence that extracellular NAD+ directly affects the heart’s natural pacemaker. When NAD+ was applied to rat sinoatrial node tissue at low concentrations, it slowed the rate of spontaneous firing and shortened the duration of action potentials, while speeding up how quickly each signal propagated through conduction fibers.⁹ In plain terms, extracellular NAD+ changed the heart’s rhythm-setting tissue in multiple ways simultaneously. This finding is from isolated tissue bathed in NAD+ solution, which is very different from what happens when you take a pill, but it illustrates why scientists take the cardiac angle seriously.

The Dose Paradox

One of the more counterintuitive findings in this area is that NAD precursors appear to be heart-protective at moderate doses but potentially harmful at high doses or with prolonged use. A broad review of the evidence concluded that experimentally elevating NAD+ improves outcomes in models of atherosclerosis, ischemia, diabetic heart disease, arrhythmia-prone cardiomyopathies, and heart failure.¹⁰ That is a genuinely impressive list. But the protection has limits.

Research using both fruit fly and mouse models found that nicotinamide, the simplest NAD precursor, has dose- and duration-dependent effects on the heart. Moderate supplementation late in life was protective, while high-dose or long-term exposure impaired cardiac function and increased arrhythmia risk.¹¹ Follow-up work showed that acute exposure to high concentrations of nicotinamide had limited effect on atrial fibrillation susceptibility in isolated hearts, suggesting the problem emerges with chronic high-dose exposure rather than a single large bolus.¹²

This dual nature helps reconcile two seemingly contradictory ideas: that NAD+ is good for the heart and that too much NAD+ might cause rhythm problems. The concentrations used in the animal studies that showed harm are far above what typical oral supplements deliver, especially given the extensive breakdown that happens before these molecules reach cardiac tissue. But the principle matters for anyone tempted to megadose, and it underscores why the “more is better” approach to supplementation can backfire.

When Researchers Deliberately Test NAD in Heart Rhythm Patients

One of the strongest indicators that the cardiology community does not view NAD supplements as acutely dangerous is that researchers are actively testing them in people with existing heart rhythm disorders. A clinical trial called HF-AF ENERGY enrolled patients with ischemic cardiomyopathy and diagnosed atrial fibrillation, all of whom had implantable cardiac defibrillators capable of continuously monitoring their heart rhythm, to test the effects of nicotinamide riboside.¹³ You would not design a trial like this if the preclinical data suggested the supplement was likely to worsen arrhythmia. The trial’s design actually reflects the opposite hypothesis: that boosting NAD+ might help reduce atrial fibrillation burden in failing hearts, consistent with the protective findings from animal studies at moderate doses.

What Might Actually Explain Palpitation Reports

If clinical trials do not show palpitations and the biology at supplement-relevant doses looks safe, why do some people report a racing or pounding heart after taking NR or NMN? Several non-NAD explanations are worth considering.

Supplement quality is a real and underappreciated variable. Independent testing of commercially available NMN products found enormous variation in actual content. The measured NMN ranged from undetectable in some products to close to label claims in others, with deviations from the labeled amount spanning from about 29% over to 100% under (meaning some capsules contained no NMN at all).¹⁴ Products that wildly miss their label claims may contain fillers, contaminants, or undisclosed ingredients. Stimulants or other bioactive compounds hiding in a poorly manufactured supplement could easily cause palpitations that the consumer then attributes to NAD.

Caffeine is another confounding factor. Many people who take NAD supplements are also consuming caffeine, and some combination products specifically include it. Research has shown that caffeine can enhance certain NAD-producing enzymes and transiently boost mitochondrial respiration when combined with NR, though continued treatment reversed some of these effects.¹⁵ Caffeine on its own is well known to trigger palpitations in sensitive individuals, and if a supplement stack includes both NAD precursors and caffeine, the latter is a far more likely culprit.

Then there is the nocebo effect and heightened body awareness. People who start a new supplement often pay more attention to how their body feels. Benign heart rhythm variations that go unnoticed on an ordinary day suddenly feel alarming when you are monitoring yourself for side effects. Occasional premature beats are extremely common in the general population and rarely indicate anything dangerous, but they can feel startling if you notice them for the first time.

The Methylation Concern

One worry that circulates in online health communities is that NAD precursors might deplete methyl donors like SAM (S-adenosylmethionine), because the body uses methyl groups when processing excess nicotinamide. Methyl-donor depletion has been loosely linked to various symptoms in alternative health circles, including heart-related complaints. The evidence, however, does not support this concern at typical supplement doses. A study of Parkinson’s disease patients taking 1,000 mg of NR daily for 30 days found no effect on global DNA methylation patterns or on levels of methylation-relevant metabolites including SAM, its byproduct SAH, adenosine, or homocysteine.¹⁶ This held true regardless of participants’ genetic variants in the methylation pathway.¹⁷ At least for short-term use at clinically studied doses, methylation disruption does not appear to be a realistic mechanism for supplement-related symptoms.

Practical Considerations if You Are Worried

If you have taken an NAD supplement and felt your heart race or flutter, the experience is real even if the cause may not be what you think. A few practical steps are worth considering. First, check what else is in the product. Many NAD supplements come in combination formulas with ingredients like caffeine, resveratrol, or pterostilbene, any of which could independently affect heart rate. Second, consider the dose. The clinical trials showing a clean safety profile used doses up to about 1,000 mg for NR and 250 mg for NMN in the elderly, with one Parkinson’s trial going as high as 3,000 mg of NR. If you are taking substantially more than these amounts, you are in uncharted territory, and the animal data on high-dose nicotinamide should give you pause. Third, if you have a diagnosed heart condition, especially atrial fibrillation or cardiomyopathy, talk to your cardiologist before starting supplementation. The HF-AF ENERGY trial is studying NR specifically in this population under close medical supervision, which is different from self-medicating with an over-the-counter product.

Timing could also matter, though the human evidence here is thin. NAD+ metabolism in the heart follows circadian rhythms, so taking a supplement at a time when cardiac NAD+ is already at its natural peak could theoretically produce a different physiological response than taking it during a trough. Nobody has tested this in a palpitation-focused study, but if you notice symptoms consistently after taking your supplement at a certain time of day, experimenting with a different time is a low-risk adjustment.

Supplement Purity as an Underrated Risk Factor

The testing data on supplement quality deserves its own emphasis because it has implications beyond palpitations. When independent researchers analyzed 18 commercially available NMN products, three contained no detectable NMN at all, and the rest showed deviations from label claims ranging from 29% over to 100% under.¹⁴ This is not a minor quality-control issue. If a product claims to contain 500 mg of NMN and actually contains none, whatever you are swallowing is something else entirely. The NAD supplement market operates with minimal regulatory oversight compared to pharmaceuticals, and the gap between what clinical trials test (pharmaceutical-grade, verified compounds) and what consumers buy off the shelf can be substantial. Any unusual symptom you experience while taking a supplement of uncertain purity could be caused by contaminants or undisclosed ingredients rather than by the NAD precursor itself.

If purity matters to you, look for products that carry third-party testing certifications and publish certificates of analysis. Products used in published clinical trials are sometimes available commercially under the same brand names, which provides at least some assurance that the formulation matches what was studied. Avoiding the cheapest options on the market is not a guarantee of quality, but products priced far below competitors raise reasonable suspicion about corners being cut during manufacturing.

NAD and the Diseased Heart

For people with existing cardiac conditions, the relationship between NAD+ and heart function takes on a different character. In cardiomyopathy, intracellular NADH levels tend to be elevated, mitochondria overproduce reactive oxygen species, and the resulting cascade reduces sodium current in heart cells. Restoring the NAD+ balance in these cells, either by directly adding NAD+ or by neutralizing the mitochondrial stress signals, brought sodium current back to normal and improved electrical conduction in both animal and human heart tissue.⁷ This suggests that in the context of heart disease, boosting NAD+ might actually reduce arrhythmia risk rather than increase it. But “might” is doing heavy lifting in that sentence. The leap from injecting NAD+ into isolated heart cells to swallowing a capsule and expecting it to reach your cardiac tissue in meaningful concentrations is enormous, and most of the precursor gets dismantled in the gut and liver before it has a chance to try.¹

The ongoing clinical trial in heart failure patients with atrial fibrillation will eventually provide more direct answers about whether oral NR affects arrhythmia burden in humans with established heart disease.¹³ Until those results are published, the honest answer for cardiac patients is that the preclinical data is cautiously encouraging, but nobody has proven it works in humans with rhythm disorders, and self-experimenting without medical guidance is not wise.